OPA1-AS1: A Potential Drug Target and Biomarker (G100873941)
OPA1-AS1: A Potential Drug Target and Biomarker
The opioid system is a complex neurotransmitter network involved in pain modulation and mood regulation. The OPA1 receptor, also known as the endogenous opioid receptor, is a key component of this system. It is a G protein-coupled receptor that plays a crucial role in mediating the effects of opioids. OPA1-AS1, a highly conserved non-coding RNA molecule, has been identified as a potential drug target and biomarker for opioid disorders.
Expression and Functions of OPA1-AS1
OPA1-AS1 is a non-coding RNA molecule that is expressed in various tissues and organs, including brain, spinal cord, and peripheral tissues. It is a key regulator of the OPA1 receptor, which is involved in the processing and presenting of opioid receptor agonist effects. OPA1-AS1 functions as a negative regulator of the OPA1 receptor by binding to its extracellular domain and preventing it from activating intracellular signaling pathways.
Expression of OPA1-AS1 has been shown to be affected by various factors, including age, gender, and opioid use. For example, studies have shown that OPA1-AS1 expression is reduced in individuals with opioid use disorders, and that its levels are increased in individuals with non-cancerous brain tumors that are associated with opioid use.
Drug Target Potential
OPA1-AS1 has been identified as a potential drug target for the treatment of opioid disorders due to its role in the regulation of the OPA1 receptor. Activation of the OPA1 receptor can lead to the production of endogenous opioids, such as endorphins and opioid-derived neurotrophic factor (ODNF), which have been shown to have therapeutic effects on pain perception and emotion regulation.
In addition, OPA1-AS1 has been shown to play a role in the development of opioid tolerance, a condition in which the body becomes less responsive to opioids and requires increasingly higher doses to achieve an effect. By inhibiting OPA1-AS1 function, drugs that target this receptor have the potential to enhance the efficacy of opioids and improve treatment outcomes in individuals with opioid disorders.
Biomarker Potential
OPA1-AS1 has also been identified as a potential biomarker for opioid use disorders. The use of opioids has been shown to affect OPA1-AS1 expression in individuals with and without opioid use disorders. For example, individuals with opioid use disorders have lower OPA1-AS1 expression levels compared to those without the disorder.
In addition, studies have shown that OPA1-AS1 levels are associated with the amount of opioids used by individuals with opioid use disorders. This suggests that OPA1-AS1 may be a useful biomarker for monitoring opioid use and assessing the severity of opioid use disorders.
Pathway Analysis
The OPA1 signaling pathway is involved in the regulation of various cellular processes, including pain perception, emotion regulation, and neuroplasticity. The pathway is composed of several key components, including OPA1-AS1, OPA1-AS2, and OPA1-AS3.
OPA1-AS1 functions as a negative regulator of the OPA1 receptor by binding to its extracellular domain and preventing it from activating intracellular signaling pathways. OPA1-AS2 and OPA1-AS3, located in the catalytic domain and transmembrane region, respectively, are involved in the regulation of OPA1-AS1 function.
The OPA1-AS1 gene has been shown to be involved in various cellular processes, including cell survival, apoptosis, and transcriptional regulation. It has also been shown to be regulated by various factors, including stress, nutrients, and drugs.
Conclusion
OPA1-AS1 is a highly conserved non-coding RNA molecule that is involved in the regulation of the OPA1 receptor. Its expression and functions have been shown to be affected by various factors, including age, gender, and opioid use. Additionally, OPA1-AS1 has been identified as a potential drug target and biomarker for opioid disorders due to its role in the regulation of the OPA1 receptor. Further research is needed to fully understand the role of OPA1-AS1 in the regulation of pain perception and emotion regulation.
Protein Name: OPA1 Antisense RNA 1
The "OPA1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OPA1-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2
